Next Phase Newsletter

A firm with offices in the USA and Middle East has raised a new $50 million fund in 2016. The firm invests $500K to $2 million in late seed stage to Series A rounds, with reserves for follow on investment. The firm primarily invests in private Healthcare IT companies. Their target ownership level is 10-20%. The firm has a flexible capital structure, and is open to investing in the form of convertible notes, debts, or equity, and will consider investments across the globe.

The firm’s primary focus is on Healthcare IT companies; companies with an integrated medical device technology component will also be considered. However the firm prefers a strong focus on the software aspect, and looks for companies in which software is the proprietary technology. Historically the firm has invested in integrated devices such as diagnostics, sequencing, healthcare analytics, and tele-medicine. The firm is highly interested in investing in technologies that are beneficial to healthcare, to improve patient experiences, and reduce healthcare costs.

The firm looks to invest in companies with established and experienced teams. The firm prefers to work with companies that are experts in their respective area. The firm looks to take a board seat, and play an active role in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A fully integrated public biopharmaceutical company with over 20 years’ operation in China’s pharmaceutical industry is interested in equity investments, in-licensing clinical stage assets for development, and will also consider collaborative R&D. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe, and is currently looking for new opportunities globally with a focus on US and EU.

Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilar, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, but can consider assets from pre-clinical to on-market stages.

The firm is seeking innovative assets that address a large unmet medical need. When making an investment, the firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life science investment firm with offices in New York and San Francisco. The firm is currently making investments out of a new $250 million venture fund backed by strategic LPs, which closed in 2016. The firm typically makes investments ranging from $5-$20 million into selected companies, most commonly in the form of equity. The firm is open to companies globally.

The firm is looking to invest in the therapeutics space and is open to considering both small molecules and biologics. The firm is looking for companies in the clinical stage that are at least post proof-of-concept. The firm is generally open to all therapeutic subsectors and indications and is particularly interested in unmet needs.

The firm is looking for management teams with experience that are backed by strong science and a solid strategy. The firm looks to act as a hands-on investor, generally taking a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The healthcare subsidiary of a multinational conglomerate is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The firm is seeking innovative medical device, diagnostic, and monitoring products to strengthen its pipeline in respiratory diseases, cardiovascular disease, and orthopedics. The firm is also interested in neurological disorders such as stroke and Parkinson’s disease, cancer, wound care, and rehabilitation for home care. The company is most interested in PMA therapeutic devices or remote monitoring devices in the homecare settings. The company prefers assets with initial patient data.

The firm is looking for assets that are compliment to its portfolio. The company prefers to own rights in the Japan market, while its partners can keep US or EU rights. The firm’s regulatory team, clinical team and support system can assist its partners with product registration and distribution in Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in New England manages over $1 billion in total assets, and is currently seeking to identify new investment opportunities in the life science space. The firm has no set time frame to make an allocation, however would invest in a firm within the next 3-6 months if a compelling opportunity was identified. Because the firm is backed by a single family and is not a typical fund that must go through the fundraising cycle, the firm has the ability to deploy capital as soon as an opportunity is sourced. The firm typically makes initial investments in the $500,000 to $1 million range although they are capable of providing more due do their funding structure and co-investor network. The firm is open to investing in companies that are based in either the US or Europe with a focus on companies based in the US.

The firm is currently most interested in companies operating in the healthcare IT space with little to no regulatory risk. The firm is willing to invest in seed and ventures stage companies often as a member of a syndicate of angels investors. For investments in medical technology or diagnostics, the firm would only participate as co-investor.

The firm prefers companies that have a pre-money valuation ranging from $3-5 million. The firm has a long-term investment horizon and likes to hold companies in their portfolio for much longer than a typical private equity firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A $50 million venture fund established by a health insurance firm aims to develop a portfolio of investments that, as a whole, focus on improving the national health care market, enhance the core business of the company and generate revenue.

These strategic investments are expected to be integrated into the company as part of its overall long-term strategy. The firm prefers to syndicate with a strong lead investor in a financing round and expects to make 5 – 7 new investments of $0.5-2 million in the coming year. The firm considers opportunities across the US and around the world with preference given to companies in the middle of the country.

The new corporate VC fund is interested in digital health technologies and care delivery models that can improve healthcare. The firm prefers products with prototype and customer traction.

The firm would like to be a strategic partner, as a payer, for startups. The firm prefers early stage teams backed by experienced management, supported by reputable early stage VC and/or angel groups that have a history of follow-on investments in Series A and B.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm with offices in the US and UK is partnering with a research organization to raise a $150 million fund focused on Regenerative Medicine (RM). Within RM, 80% of the fund will be towards immunotherapies, cell and gene therapies while the remaining 20% of the fund will be towards enabling-technologies that move RM forward in commercialization and medicine. The firm is looking to build a portfolio of 10-15 early stage RM companies, investing up to $10 million per deal with an initial investment of $1-3 million. The firm prefers to lead investments, though is willing to co-invest. The partnership recently launched the building of cell manufacturing and process manufacturing facilities for GMP, process development, and vector manufacturing that will enable the optimized production of cell lines and tissues necessary for early clinical development of RM technologies. All companies the firm invests in will have the valuable opportunity and prioritized access to the facility in developing their technology. The firm invests globally in RM companies, particularly those RM companies open to leveraging the existing infrastructure local to the firm’s partner organization.

The firm focuses exclusively on regenerative medicine, including stem cells, cell therapies, immunotherapies, and tissue engineering. The firm is interested in RM therapeutics, and is actively looking at several immunotherapies, such as those involving T-cells, dendritic cells, and/or checkpoint inhibitors. The firm is open to any indication in the therapeutic and medical device space, as long as the underlying RM technology is robust, and has demonstrated efficacy that is not incremental, but rather a dramatic change in the way the disease is currently treated. The firm invests in early projects, primarily from the pre-clinical stage through Phase II.

The firm is looking for compelling RM technologies, and is prepared to build or augment the management team and/or board of a company, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com